BMEA — Biomea Fusion Share News
0.000.00%
Last trade - 00:00U.S. STOCKS ON THE MOVE-DXC Technology, Nvidia, Lisata Therapeutics
Biomea doses first patient in early-stage blood cancer study; shares rise
Brief: Biomea Fusion Announces First Patient Dosed With Covalent FLT3 Inhibitor BMF-500 In Relapsed Or Refractory Acute Leukemia In Phase I Clinical Trial
Brief: Biomea Fusion Announces FDA Clearance Of Investigational New Drug (IND) Application For BMF-219 In Type 1 Diabetes
Brief: Biomea Fusion Announces FDA And Health Canada Clearance Of The Expansion Cohorts Of The Ongoing Covalent-111 Phase Ii Study
Brief: Biomea Fusion Says BMF-219 Induces Complete Responses In Patients With Acute Myeloid Leukemia
U.S. STOCKS ON THE MOVE-Copper miners, Benitec Biopharma, SL Green
U.S. STOCKS ON THE MOVE-Wolfspeed, Papa John, Chart Industries
Biomea Fusion up after positive data from diabetes drug study
U.S. RESEARCH ROUNDUP-Dice Therapeutics, Mongodb, Valvoline
Brief: Biomea Fusion Presents Positive Clinical Data From Initial Cohorts Of Ongoing Phase Ii Study (Covalent-111) Of Bmf-219
U.S. RESEARCH ROUNDUP- Galecto, Palo Alto Networks, Zscaler
U.S. RESEARCH ROUNDUP-E2open, Molson Coors Beverage Co, Premier
Brief: Biomea Fusion Reports First Quarter 2023 Financial Results And Corporate Highlights
U.S. STOCKS ON THE MOVE-US banks, Biomea Fusion, Tutor Perini
Biomea Fusion rises on FDA clearance to start trial for leukemia treatment
Brief: Biomea Fusion Announces FDA Clearance Of Investigational New Drug Application For Covalent FLT3 Inhibitor Bmf-500 In Relapsed Or Refractory Acute Leukemia
Brief: Biomea Fusion To Present Late Breaking Data From Ongoing Phase II Trial, Covalent-111, Evaluating Bmf-219 In Patients With Type 2 Diabetes, At The ADA 83rd Scientific Sessions 2023 In June
Brief: Biomea Fusion Announces Closing Of Upsized Public Offering